Global and rising public health issuesLife is a health journey, and the global trends toward longer life expectancies and increasingly more sedentary lifestyles have made diabetes and cardiovascular disease worldwide public health concerns.
Around 425 million people lived with diabetes in 2016 and the figure is expected to rise over 640 million by 2040 (source: International Diabetes Federation)
An estimated 17.7 million people died from cardiovascular diseases in 2015 (source: WHO)
The path forwardThe effects of diabetes and cardiovascular disease are severe, particularly because many people live with both. Research has, however, helped turn these diseases into chronic conditions that can be treated, and many people now live longer, more active and more fulfilling lives.
Diabetes is caused by either a lack of insulin in the body (type 1) or the inability of the body to use the insulin it produces (type 2). At Sanofi, we have been developing insulin treatments for diabetes for close to a century. We offer a comprehensive portfolio of diabetes medicines, including insulins, to lower blood sugar levels and today, more than 50% of people on once-daily basal insulin treatments are supported by Sanofi.
Cardiovascular disease is a group of disorders of the heart and blood vessels. Building on Sanofi’s legacy of more than 50 years of fighting cardiovascular disease, we deliver innovative therapeutic solutions for cardiovascular conditions to people at high risk for cardiac events (such as a heart attack) and who need additional treatment options beyond currently available medications.
But challenges remain
People living with diabetes and cardiovascular disease still face many challenges. They see their doctors only few times a year; miss support in between; and need to adapt their nutrition, exercise and medication.
Diabetes and cardiovascular disease are also a burden for healthcare systems worldwide, due to the increasing number of cases and associated healthcare costs.
Even as therapeutic solutions become more effective, we recognize that the management of these diseases is a 24/7 job. As a health journey partner, we at Sanofi focus on improving quality of life.
The importance of an integrated approach
We build on our heritage and commitment to innovation to improve quality of life and support patients and healthcare systems by offering more than medicines. By combining Sanofi’s quality drugs with services, devices and data management, we aim at giving new hope to millions of people.
Our integrated care solutions aim to improve outcomes and patient experiences. We have developed innovative, value-based medicines and connected solutions designed to address the most urgent medical and societal needs. Through this work, our purpose is to help people with diabetes and cardiovascular disease improving their quality of life, and we aim at supporting the sustainability of healthcare systems.
With strong in-house capabilities focusing on titration guidance and improved connectivity, we also work with partners who share the same ambitions. In 2016, we partnered with Verily (an Alphabet company) to found Onduo, a joint-venture focusing on holistic solutions to improve diabetes management.